Skip to main content
Chabiotech Co.,Ltd. logo

Chabiotech Co.,Ltd. — Investor Relations & Filings

Ticker · 085660 ISIN · KR7085660009 KO Professional, scientific and technical activities
Open in API
Filings indexed 460 across all filing types
Latest filing 2022-03-18 Major Shareholding Noti…
Country KR South Korea
Listing KO 085660

About Chabiotech Co.,Ltd.

http://en.chabio.com/

Chabiotech Co., Ltd. is a biotechnology company specializing in the research and development of cell and gene therapies for rare cancers and incurable diseases. The company's core activities include advancing its therapeutic pipelines and providing global Contract Development and Manufacturing Organization (CDMO) services for advanced biopharmaceuticals, including full-scale GMP production and testing. Chabiotech also operates bio-banking services, such as cord blood and immune/stem cell storage, utilizing advanced cryopreservation technology. Its diversified business segments extend to genomics for precision medicine, healthcare IT solutions that integrate AI and Big Data, comprehensive wellness programs, and specialized healthcare consulting.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea (often referred to as a 5% report). It details the shareholding status, changes in ownership, and special relationships of major shareholders. This falls under the category of 'Major Shareholding Notification' (MRQ).
2022-03-18 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report Submission' (감사보고서 제출) filed by Cha Biotech. It contains the auditor's opinion, financial statements (consolidated and separate), and details regarding the audit results. While it provides financial data, it is specifically the regulatory filing of the audit report itself, not a full Annual Report (10-K) or a simple announcement of a report (RPA). In the context of Korean regulatory filings (DART/KIND), this is classified as an Audit Report. FY 2021
2022-03-18 Korean
사업보고서 (2021.12)
Audit Report / Information Classification · 100% confidence The document is a 'Consolidated Audit Report' (연결감사보고서) for Cha Biotech (차바이오텍) for the fiscal year ending December 31, 2021. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. This is a formal audit document, not an annual report (10-K) or an earnings release, and it is clearly the full audit report rather than an announcement of one. FY 2021
2022-03-18 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Cha Biotech. It outlines the date, location, and agenda items for the upcoming Annual General Meeting (AGM), including the election of directors and approval of financial statements. This type of document is a standard proxy solicitation and information statement provided to shareholders to inform them of meeting details and agenda items, which falls under the Proxy Solicitation & Information Statement category.
2022-03-14 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Cha Biotech. It contains the meeting agenda, date, location, and details regarding electronic voting, as well as management information such as director activities and remuneration. This type of document is a standard proxy statement/notice sent to shareholders to inform them of an upcoming meeting and solicit their votes, which falls under the Proxy Solicitation & Information Statement category.
2022-03-14 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea used by companies to solicit proxies from shareholders for an upcoming Annual General Meeting (AGM). It contains details about the meeting date, agenda items (such as approval of financial statements and director appointments), and instructions for electronic voting. While it contains financial summary data, the primary purpose of this specific document is to solicit proxies for the AGM, making it a Proxy Solicitation & Information Statement.
2022-03-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.